Compare COSM & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | COSM | CMMB |
|---|---|---|
| Founded | 2009 | 2004 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Other Pharmaceuticals | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.4M | 13.8M |
| IPO Year | 2013 | N/A |
| Metric | COSM | CMMB |
|---|---|---|
| Price | $0.50 | $2.06 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $26.50 |
| AVG Volume (30 Days) | ★ 616.4K | 93.1K |
| Earning Date | 11-17-2025 | 11-20-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $59,792,819.00 | N/A |
| Revenue This Year | $28.14 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 6.69 | N/A |
| 52 Week Low | $0.28 | $2.21 |
| 52 Week High | $1.32 | $9.84 |
| Indicator | COSM | CMMB |
|---|---|---|
| Relative Strength Index (RSI) | 38.52 | 31.68 |
| Support Level | $0.41 | $2.01 |
| Resistance Level | $0.46 | $2.77 |
| Average True Range (ATR) | 0.05 | 0.21 |
| MACD | 0.00 | -0.04 |
| Stochastic Oscillator | 37.87 | 6.58 |
Cosmos Health Inc is engaged in the nutraceuticals sector through its own proprietary lines of products 'Sky Premium Life' and 'Mediterranation'. Additionally, the firm is operating in the pharmaceutical sector through the provision of a broad line of branded over-the-counter drugs and branded and generic medicines. The company's focus will be on Branded Pharmaceuticals, Over-the-Counter medicines, and Generic Pharmaceuticals. It provides its products to wholesale drug distributors, wholesalers, and retail healthcare providers. The company's segment are Wholesale, Pharma Manufacturing, Nutraceuticals & Pharmaceuticals and Other. It derives maximum revenue from Wholesale Segment.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.